郑荣寿 , 张思维 , 孙可欣 , 等 . 2016年中国恶性肿瘤流行情况分析 [J ] . 中华肿瘤杂志 , 2023 , 45 ( 3 ): 212 - 220 .

ZHENG R S , ZHANG S W , SUN K X , et al . Cancer statistics in China, 2016 [J ] . Chin J Oncol , 2023 , 45 ( 3 ): 212 - 220 .

DENOIX P . Ongoing investigation in cancer centers [J ] . Bull Inst Natl Hyg , 1946 , 1 : 12 - 7 .

吴怀申 , 何雍毅 . 恶性肿瘤的TNM分类法 [J ] . 癌症 , 1999 ( 1 ): 104 - 105 .

WU H S , HE Y Y . TNM classification of malignant tumors [J ] . Chin J Cancer , 1999 ( 1 ): 104 - 105 .

RAMI-PORTA R . Future perspectives on the TNM Staging for lung cancer [J ] . Cancers (Basel) , 2021 , 13 ( 8 ): 1940.

日本胃癌学会 . 胃癌处理规约 [M ] . 1版. 东京 : 金原出版株式会社 , 1962 .

Japanese Gastric Cancer Association . Gastric cancer management protocol [M ] . 1 edition. Tokyo : Kanehara Publishing Co., LTD , 1962 .

日本胃癌学会 . 胃癌处理规约 [M ] . 14版. 东京 : 金原出版株式会社 , 2010 .

Japanese Gastric Cancer Association . Gastric cancer management protocol [M ] . 14 edition. Tokyo : Kanehara Publishing Co., LTD , 2010 .

CUSCHIERI A , WEEDEN S , FIELDING J , et al . Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group [J ] . Br J Cancer , 1999 , 79 ( 9/10 ): 1522 - 1530 . DOI: 10.1038/sj.bjc.6690243 http://doi.org/10.1038/sj.bjc.6690243

BONENKAMP J J , HERMANS J , SASAKO M , et al . Extended lymph-node dissection for gastric cancer [J ] . N Engl J Med , 1999 , 340 ( 12 ): 908 - 914 . DOI: 10.1056/NEJM199903253401202 http://doi.org/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202

SONGUN I , PUTTER H , KRANENBARG E M , et al . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial [J ] . Lancet Oncol , 2010 , 11 ( 5 ): 439 - 449 . DOI: 10.1016/S1470-2045(10)70070-X http://doi.org/10.1016/S1470-2045(10)70070-X

SASAKO M , SANO T , YAMAMOTO S , et al . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer [J ] . N Engl J Med , 2008 , 359 ( 5 ): 453 - 462 . DOI: 10.1056/NEJMoa0707035 http://doi.org/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035

MACDONALD J S , SMALLEY S R , BENEDETTI J , et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J ] . N Engl J Med , 2001 , 345 ( 10 ): 725 - 730 . DOI: 10.1056/NEJMoa010187 http://doi.org/10.1056/NEJMoa010187 http://www.nejm.org/doi/abs/10.1056/NEJMoa010187 http://www.nejm.org/doi/abs/10.1056/NEJMoa010187

CUNNINGHAM D , ALLUM W H , STENNING S P , et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J ] . N Engl J Med , 2006 , 355 ( 1 ): 11 - 20 . DOI: 10.1056/NEJMoa055531 http://doi.org/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J ] . Lancet , 2019 , 393 ( 10184 ): 1948 - 1957 . DOI: 10.1016/S0140-6736(18)32557-1 http://doi.org/10.1016/S0140-6736(18)32557-1 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571

KANG Y K , KIM H D , YOOK J H , et al . Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial [J ] . J Clin Oncol , 2023 , 41 ( 16 _suppl): 4067.

ZHANG X T , LIANG H , LI Z Y , et al . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Oncol , 2021 , 22 ( 8 ): 1081 - 1092 . DOI: 10.1016/S1470-2045(21)00297-7 http://doi.org/10.1016/S1470-2045(21)00297-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977

IWASAKI Y , TERASHIMA M , MIZUSAWA J , et al . Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial [J ] . Gastric Cancer , 2021 , 24 ( 2 ): 492 - 502 . DOI: 10.1007/s10120-020-01136-7 http://doi.org/10.1007/s10120-020-01136-7

SAKURAMOTO S , SASAKO M , YAMAGUCHI T , et al . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [J ] . N Engl J Med , 2007 , 357 ( 18 ): 1810 - 1820 . DOI: 10.1056/NEJMoa072252 http://doi.org/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252

SASAKO M , SAKURAMOTO S , KATAI H , et al . Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer [J ] . J Clin Oncol , 2011 , 29 ( 33 ): 4387 - 4393 . DOI: 10.1200/JCO.2011.36.5908 http://doi.org/10.1200/JCO.2011.36.5908 https://ascopubs.org/doi/10.1200/JCO.2011.36.5908 https://ascopubs.org/doi/10.1200/JCO.2011.36.5908

KAKEJI Y , YOSHIDA K , KODERA Y , et al . Three-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage Ⅲ gastric cancer: JACCRO GC-07 [J ] . Gastric Cancer , 2022 , 25 ( 1 ): 188 - 196 . DOI: 10.1007/s10120-021-01224-2 http://doi.org/10.1007/s10120-021-01224-2

BANG Y J , KIM Y W , YANG H K , et al . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J ] . Lancet , 2012 , 379 ( 9813 ): 315 - 321 . DOI: 10.1016/S0140-6736(11)61873-4 http://doi.org/10.1016/S0140-6736(11)61873-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734

LEE J , LIM D H , KIM S , et al . Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial [J ] . J Clin Oncol , 2012 , 30 ( 3 ): 268 - 273 .

PARK S H , LIM D H , SOHN T S , et al . A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial [J ] . Ann Oncol , 2021 , 32 ( 3 ): 368 - 374 . DOI: 10.1016/j.annonc.2020.11.017 http://doi.org/10.1016/j.annonc.2020.11.017 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431722 https://linkinghub.elsevier.com/retrieve/pii/S0923753420431722

KITANO S , ISO Y , MORIYAMA M , et al . Laparoscopy-assisted billroth I gastrectomy [J ] . Surg Laparosc Endosc , 1994 , 4 ( 2 ): 146 - 148 .

KIM H H , HAN S U , KIM M C , et al . Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial [J ] . JAMA Oncol , 2019 , 5 ( 4 ): 506 - 513 . DOI: 10.1001/jamaoncol.2018.6727 http://doi.org/10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727

KATAI H , MIZUSAWA J , KATAYAMA H , et al . Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Gastroenterol Hepatol , 2020 , 5 ( 2 ): 142 - 151 .

ZENG Y K , YANG Z L , PENG J S , et al . Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials [J ] . Ann Surg , 2012 , 256 ( 1 ): 39 - 52 . DOI: 10.1097/SLA.0b013e3182583e2e http://doi.org/10.1097/SLA.0b013e3182583e2e https://journals.lww.com/00000658-201207000-00008 https://journals.lww.com/00000658-201207000-00008

LIU F L , HUANG C M , XU Z K , et al . Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1590 - 1597 . DOI: 10.1001/jamaoncol.2020.3152 http://doi.org/10.1001/jamaoncol.2020.3152 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669

YU J , HUANG C M , SUN Y H , et al . Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial [J ] . JAMA , 2019 , 321 ( 20 ): 1983 - 1992 . DOI: 10.1001/jama.2019.5359 http://doi.org/10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359

HUANG C M , LIU H , HU Y F , et al . Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial [J ] . JAMA Surg , 2022 , 157 ( 1 ): 9 - 17 . DOI: 10.1001/jamasurg.2021.5104 http://doi.org/10.1001/jamasurg.2021.5104 https://jamanetwork.com/journals/jamasurgery/fullarticle/2785366 https://jamanetwork.com/journals/jamasurgery/fullarticle/2785366

HYUNG W J , YANG H K , PARK Y K , et al . Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial [J ] . J Clin Oncol , 2020 , 38 ( 28 ): 3304 - 3313 . DOI: 10.1200/JCO.20.01210 http://doi.org/10.1200/JCO.20.01210

ETOH T , OHYAMA T , SAKURAMOTO S , et al . Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial [J ] . JAMA Surg , 2023 , 158 ( 5 ): 445 - 454 . DOI: 10.1001/jamasurg.2023.0096 http://doi.org/10.1001/jamasurg.2023.0096 https://jamanetwork.com/journals/jamasurgery/fullarticle/2802654 https://jamanetwork.com/journals/jamasurgery/fullarticle/2802654

PARK Y M , CHO E , KANG H Y , et al . The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis [J ] . Surg Endosc , 2011 , 25 ( 8 ): 2666 - 2677 . DOI: 10.1007/s00464-011-1627-z http://doi.org/10.1007/s00464-011-1627-z http://link.springer.com/10.1007/s00464-011-1627-z http://link.springer.com/10.1007/s00464-011-1627-z

FACCIORUSSO A , ANTONINO M , MASO M D , et al . Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: a meta-analysis [J ] . World J Gastrointest Endosc , 2014 , 6 ( 11 ): 555 - 563 . DOI: 10.4253/wjge.v6.i11.555 http://doi.org/10.4253/wjge.v6.i11.555 http://www.wjgnet.com/1948-5190/full/v6/i11/555.htm http://www.wjgnet.com/1948-5190/full/v6/i11/555.htm

JAPANESE GASTRIC CANCER ASSOCIATION . Japanese gastric cancer treatment guidelines 2010 (ver. 3) [J ] . Gastric Cancer , 2011 , 14 ( 2 ): 113 - 123 . DOI: 10.1007/s10120-011-0042-4 http://doi.org/10.1007/s10120-011-0042-4

JAPANESE GASTRIC CANCER ASSOCIATION . Japanese gastric cancer treatment guidelines 2014 (ver. 4) [J ] . Gastric Cancer , 2017 , 20 ( 1 ): 1 - 19 . DOI: 10.1007/s10120-016-0622-4 http://doi.org/10.1007/s10120-016-0622-4

HASUIKE N , ONO H , BOKU N , et al . A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607) [J ] . Gastric Cancer , 2018 , 21 ( 1 ): 114 - 123 . DOI: 10.1007/s10120-017-0704-y http://doi.org/10.1007/s10120-017-0704-y

JAPANESE GASTRIC CANCER ASSOCIATION . Japanese gastric cancer treatment guidelines 2018 (5th edition) [J ] . Gastric Cancer , 2021 , 24 ( 1 ): 1 - 21 . DOI: 10.1007/s10120-020-01042-y http://doi.org/10.1007/s10120-020-01042-y

TAKIZAWA K , ONO H , HASUIKE N , et al . A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010) [J ] . Gastric Cancer , 2021 , 24 ( 2 ): 479 - 491 . DOI: 10.1007/s10120-020-01134-9 http://doi.org/10.1007/s10120-020-01134-9

ASSOCIATION J G C . Japanese gastric cancer treatment guidelines 2021 (6th edition) [J ] . Gastric Cancer , 2023 , 26 ( 1 ): 1 - 25 . DOI: 10.1007/s10120-022-01331-8 http://doi.org/10.1007/s10120-022-01331-8

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

HECHT J R , BANG Y J , QIN S K , et al . Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC: a randomized phase Ⅲ trial [J ] . J Clin Oncol , 2016 , 34 ( 5 ): 443 - 451 .

SATOH T , XU R H , CHUNG H C , et al . Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN: a randomized, phase Ⅲ study [J ] . J Clin Oncol , 2014 , 32 ( 19 ): 2039 - 2049 . DOI: 10.1200/JCO.2013.53.6136 http://doi.org/10.1200/JCO.2013.53.6136 https://ascopubs.org/doi/10.1200/JCO.2013.53.6136 https://ascopubs.org/doi/10.1200/JCO.2013.53.6136

TABERNERO J , HOFF P M , SHEN L , et al . Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study [J ] . Lancet Oncol , 2018 , 19 ( 10 ): 1372 - 1384 . DOI: S1470-2045(18)30481-9 http://doi.org/S1470-2045(18)30481-9

THUSS-PATIENCE P C , SHAH M A , OHTSU A , et al . Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study [J ] . Lancet Oncol , 2017 , 18 ( 5 ): 640 - 653 . DOI: 10.1016/S1470-2045(17)30111-0 http://doi.org/10.1016/S1470-2045(17)30111-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301110 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301110

SHITARA K , BANG Y J , IWASA S , et al . Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer [J ] . N Engl J Med , 2020 , 382 ( 25 ): 2419 - 2430 . DOI: 10.1056/NEJMoa2004413 http://doi.org/10.1056/NEJMoa2004413 http://www.nejm.org/doi/10.1056/NEJMoa2004413 http://www.nejm.org/doi/10.1056/NEJMoa2004413

VAN CUTSEM E , BARTOLOMEO M D , SMYTH E , et al . Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study [J ] . Lancet Oncol , 2023 , 24 ( 7 ): 744 - 756 . DOI: 10.1016/S1470-2045(23)00215-2 http://doi.org/10.1016/S1470-2045(23)00215-2

PENG Z , LIU T S , WEI J , et al . A phase Ⅱ study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers [J ] . J Clin Oncol , 2020 , 38 ( 15 _suppl): 4560.

SHITARA K , LORDICK F , BANG Y J , et al . Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial [J ] . Lancet , 2023 , 401 ( 10389 ): 1655 - 1668 . DOI: 10.1016/S0140-6736(23)00620-7 http://doi.org/10.1016/S0140-6736(23)00620-7

SHAH M A , SHITARA K , AJANI J A , et al . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial [J ] . Nat Med , 2023 , 29 ( 8 ): 2133 - 2141 . DOI: 10.1038/s41591-023-02465-7 http://doi.org/10.1038/s41591-023-02465-7

KANG Y K , BOKU N , SATOH T , et al . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet , 2017 , 390 ( 10111 ): 2461 - 2471 . DOI: 10.1016/S0140-6736(17)31827-5 http://doi.org/10.1016/S0140-6736(17)31827-5 https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275 https://linkinghub.elsevier.com/retrieve/pii/S0140673617318275

JANJIGIAN Y Y , SHITARA K , MOEHLER M , et al . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J ] . Lancet , 2021 , 398 ( 10294 ): 27 - 40 . DOI: 10.1016/S0140-6736(21)00797-2 http://doi.org/10.1016/S0140-6736(21)00797-2

SHITARA K , ÖZGÜROĞLU M , BANG Y J , et al . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J ] . Lancet , 2018 , 392 ( 10142 ): 123 - 133 . DOI: S0140-6736(18)31257-1 http://doi.org/S0140-6736(18)31257-1

BOKU N , RYU M H , KATO K , et al . Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4) [J ] . Ann Oncol , 2019 , 30 ( 2 ): 250 - 258 . DOI: 10.1093/annonc/mdy540 http://doi.org/10.1093/annonc/mdy540 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310361 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310361

XU J , JIANG H , PAN Y , et al . LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase Ⅲ study [J ] . Ann Oncol , 2021 , 32 : S1331 .

MOEHLER M H , KATO K , ARKENAU H T , et al . Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) [J ] . J Clin Oncol , 2023 , 41 ( 4 _suppl): 286.

RHA S Y , OH D Y , YAÑEZ P , et al . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial [J ] . Lancet Oncol , 2023 , 24 ( 11 ): 1181 - 1195 . DOI: 10.1016/S1470-2045(23)00515-6 http://doi.org/10.1016/S1470-2045(23)00515-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156 https://linkinghub.elsevier.com/retrieve/pii/S1470204523005156

JANJIGIAN Y Y , KAWAZOE A , YANEZ P E , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: initial findings of the global phase 3 KEYNOTE-811 study [J ] . J Clin Oncol , 2021 , 39 ( 15 _suppl): 4013.

JANJIGIAN Y Y , KAWAZOE A , BAI Y , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: survival results from the phase Ⅲ, randomized, double-blind, placebo-controlled KEYNOTE-811 study [J ] . Ann Oncol , 2023 , 34 : S851 -S852. DOI: 10.1016/j.annonc.2023.09.1424 http://doi.org/10.1016/j.annonc.2023.09.1424 https://linkinghub.elsevier.com/retrieve/pii/S0923753423022615 https://linkinghub.elsevier.com/retrieve/pii/S0923753423022615

YUAN S Q , NIE R C , JIN Y , et al . Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: results from a prospective, randomized, open-label, phase Ⅱ trial [J ] . J Clin Oncol , 2023 , 41 ( 16 _suppl): 4001.

DING X W , WANG X J , LI B , et al . PERSIST: A multicenter, randomized phase Ⅱ trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC) [J ] . J Clin Oncol , 2023 , 41 ( 4 _suppl): 364.

AL-BATRAN S E , LORENZEN S , THUSS-PATIENCE P C , et al . Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase Ⅱb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK [J ] . J Clin Oncol , 2022 , 40 ( 16 _sup pl): 4003.

THRIFT A P , WENKER T N , EL-SERAG H B . Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention [J ] . Nat Rev Clin Oncol , 2023 , 20 ( 5 ): 338 - 349 . DOI: 10.1038/s41571-023-00747-0 http://doi.org/10.1038/s41571-023-00747-0

CORDLE F . The use of epidemiology, scientific data, and regulatory authority to determine risk factors in cancers of some organs of the digestive system. 5. Stomach cancer [J ] . Regul Toxicol Pharmacol , 1986 , 6 ( 2 ): 171 - 180 . DOI: 10.1016/0273-2300(86)90032-2 http://doi.org/10.1016/0273-2300(86)90032-2 https://linkinghub.elsevier.com/retrieve/pii/0273230086900322 https://linkinghub.elsevier.com/retrieve/pii/0273230086900322

ASAKA M . A new approach for elimination of gastric cancer deaths in Japan [J ] . Int J Cancer , 2013 , 132 ( 6 ): 1272 - 1276 . DOI: 10.1002/ijc.27965 http://doi.org/10.1002/ijc.27965

ASAKA M , KATO M , SAKAMOTO N . Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan [J ] . J Gastroenterol , 2014 , 49 ( 1 ): 1 - 8 . DOI: 10.1007/s00535-013-0897-8 http://doi.org/10.1007/s00535-013-0897-8

CHOI K S , SUH M . Screening for gastric cancer: the usefulness of endoscopy [J ] . Clin Endosc , 2014 , 47 ( 6 ): 490 - 496 . DOI: 10.5946/ce.2014.47.6.490 http://doi.org/10.5946/ce.2014.47.6.490

CHEN Z H , LIN L , WU C F , et al . Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine [J ] . Cancer Commun , 2021 , 41 ( 11 ): 1100 - 1115 . DOI: 10.1002/cac2.v41.11 http://doi.org/10.1002/cac2.v41.11 https://onlinelibrary.wiley.com/toc/25233548/41/11 https://onlinelibrary.wiley.com/toc/25233548/41/11

JUMPER J , EVANS R , PRITZEL A , et al . Highly accurate protein structure prediction with AlphaFold [J ] . Nature , 2021 , 596 ( 7873 ): 583 - 589 . DOI: 10.1038/s41586-021-03819-2 http://doi.org/10.1038/s41586-021-03819-2